These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 20103634)

  • 1. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
    Myers R; Harvey M; Kaufmann TJ; Greiner SM; Krempski JW; Raffel C; Shelton SE; Soeffker D; Zollman P; Federspiel MJ; Blanco M; Galanis E
    Hum Gene Ther; 2008 Jul; 19(7):690-8. PubMed ID: 18576918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
    Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
    Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
    Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
    Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
    McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
    Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
    Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ
    Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
    Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
    Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
    Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
    BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
    Msaouel P; Dispenzieri A; Galanis E
    Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
    Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
    Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
    Galanis E; Dooley KE; Keith Anderson S; Kurokawa CB; Carrero XW; Uhm JH; Federspiel MJ; Leontovich AA; Aderca I; Viker KB; Hammack JE; Marks RS; Robinson SI; Johnson DR; Kaufmann TJ; Buckner JC; Lachance DH; Burns TC; Giannini C; Raghunathan A; Iankov ID; Parney IF
    Nat Commun; 2024 Jan; 15(1):493. PubMed ID: 38216554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
    Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
    BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.